Uploaded November 2025 | Updated September 2026, 2 weeks ago

---

Welcome to another compelling episode of #ExpertTalk by EverythingALS!
In this session, we’re joined by Dr. Oren Levy, Medical Director, Early Clinical Development, Regeneron Pharmaceuticals and Dr. Olga Uspenskaya-Cadoz, Chief Medical Officer, VectorY Therapeutics.

Drs Levy and Uspenskaya-Cadoz discussed:
• Progress on a new siRNA therapy for SOD1-ALS, focused on slowing disease progression through precision targeting (Dr. Levy).
• Vectory Therapeutics introduced VTX002, an innovative gene therapy aimed at TDP43, advancing global trials that could redefine ALS treatment.
• Both speakers emphasized collaboration, biomarkers, and patient-driven innovation as key to accelerating breakthroughs in ALS research.


📲 Download the EverythingALS App:
- Google Playstore: bit.ly/4nXqIYy
- App Store: bit.ly/42tPBmh

Follow EverythingALS:
► Website: everythingals.org
► Twitter: https://x.com/everything_als
► LinkedIn: linkedin.com/everythingals
► Facebook: facebook.com/EverythingALS
► Subscribe for more Expert Talks: youtube.com/c/everythingals

#ExpertTalk #ALSResearch #ALSBiobanking #ALSClinicalTrials #EverythingALS #ALSCommunity #NeurodegenerativeDiseases #PatientCenteredResearch #ALSAdvocacy #CollaborativeScience #ALSNetwork #MotorNeuronDisease #ALSUpdates #ALSExperts

🔔 If you're passionate about advancing ALS care and research — like, subscribe, and turn on notifications.

Share this episode to raise awareness and support for the ALS community.